EP0888381A4 - Zielgerichtete therapeutische und diagnostische mittel, methoden zu deren herstellung und verwendung - Google Patents

Zielgerichtete therapeutische und diagnostische mittel, methoden zu deren herstellung und verwendung

Info

Publication number
EP0888381A4
EP0888381A4 EP96945796A EP96945796A EP0888381A4 EP 0888381 A4 EP0888381 A4 EP 0888381A4 EP 96945796 A EP96945796 A EP 96945796A EP 96945796 A EP96945796 A EP 96945796A EP 0888381 A4 EP0888381 A4 EP 0888381A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic
preparing
methods
same
diagnostic target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96945796A
Other languages
English (en)
French (fr)
Other versions
EP0888381A1 (de
Inventor
Edwin L Madison
Jeffrey W Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP0888381A1 publication Critical patent/EP0888381A1/de
Publication of EP0888381A4 publication Critical patent/EP0888381A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP96945796A 1995-12-21 1996-12-19 Zielgerichtete therapeutische und diagnostische mittel, methoden zu deren herstellung und verwendung Ceased EP0888381A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US902895P 1995-12-21 1995-12-21
US9028P 1995-12-21
PCT/US1996/020577 WO1997039021A1 (en) 1995-12-21 1996-12-19 Targeted therapeutic or diagnostic agents and methods of making and using same

Publications (2)

Publication Number Publication Date
EP0888381A1 EP0888381A1 (de) 1999-01-07
EP0888381A4 true EP0888381A4 (de) 2001-10-17

Family

ID=21735166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96945796A Ceased EP0888381A4 (de) 1995-12-21 1996-12-19 Zielgerichtete therapeutische und diagnostische mittel, methoden zu deren herstellung und verwendung

Country Status (5)

Country Link
EP (1) EP0888381A4 (de)
JP (1) JP2000506854A (de)
AU (1) AU1821397A (de)
CA (1) CA2241051A1 (de)
WO (1) WO1997039021A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
JP2003508497A (ja) * 1999-09-08 2003-03-04 バイエル アクチェンゲゼルシャフト インテグリンに媒介される薬物ターゲッティング
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1383884A4 (de) 2001-03-22 2004-12-15 Dendreon Corp Serinprotease cvsp14 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
JP5398945B2 (ja) 2001-04-23 2014-01-29 マリンクロッド エルエルシー ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US20090317329A2 (en) * 2005-07-05 2009-12-24 Baker Idi Heart & Diabetes Institute Holdings Limited Anticoagulation agent and uses thereof
WO2008068280A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
MX2021008832A (es) 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271227A2 (de) * 1986-11-12 1988-06-15 The General Hospital Corporation Rekombinante Hybrid-Immunoglobulinmoleküle sowie deren Verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271227A2 (de) * 1986-11-12 1988-06-15 The General Hospital Corporation Rekombinante Hybrid-Immunoglobulinmoleküle sowie deren Verwendung

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Barbas et al: (1993) PNAS 90, 10003-10007. *
BODE, CHRISTOPH ET AL: "Platelet - targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation", CIRCULATION (1991), 84(2), 805-13, XP001010586 *
DEWERCHIN, M. ET AL: "Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo", BLOOD (1991), 78(4), 1005-18, XP001010583 *
Hashino et al: (1992) J. Biochem. 112, 547-551. *
HASKEL E.J. ET AL: "Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.", CIRCULATION, (1991) 83/3 (1048-1056)., XP000993163 *
NEBLOCK, DONALD S. ET AL: "Conjugation and evaluation of 7E3 x P4B6, a chemically crosslinked bispecific F(ab')2 antibody which inhibits platelet aggregation and localizes tissue plasminogen activator to the platelet surface", BIOCONJUGATE CHEM. (1992), 3(2), 126-31, XP002173015 *
See also references of WO9739021A1 *
Smith et al: (1994) JBC 264, 32788-32795. *
SMITH, JEFFREY W. ET AL: "Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin.alpha.IIb.beta.3", J. BIOL. CHEM. (1995), 270(51), 30486-90, XP002173014 *
SWENSON, S. (1) ET AL: "A platelet targeted thrombolytic agent: Covalent modification with a platelet avid peptide.", FASEB JOURNAL, (1997) VOL. 11, NO. 9, PP. A1401. MEETING INFO.: 17TH INTERNATIONAL CONGRESS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY IN CONJUNCTION WITH THE ANNUAL MEETING OF THE AMERICAN SOCIETY FO BIOCHEMISTRY AND MOLECULAR BIOLOGY SAN FRANCISCO, CALI, XP000993094 *
Yamada et al: (1993) JBC 268,10588-10592. *
Yamada et al: (1994) JBC 270, 5687-5690. *

Also Published As

Publication number Publication date
AU1821397A (en) 1997-11-07
WO1997039021A1 (en) 1997-10-23
EP0888381A1 (de) 1999-01-07
JP2000506854A (ja) 2000-06-06
CA2241051A1 (en) 1997-10-23

Similar Documents

Publication Publication Date Title
FR2729845B1 (fr) Catheter d'imagerie echographique endocavitaire
DE69312317D1 (de) Überprüfung von milchvieh
MA23065A1 (fr) Microspheres de proteines vegetales modifies hydrolysees et leurs procedes de preparation et d'utilisation.
DE69529307D1 (de) Ultraschall-Diagnose- und Behandlungssystem
FI935424A7 (fi) Sähkökirurginen ja ultraäänikirurginen järjestelmä
EP0869804A4 (de) Supplementierte und nichtsupplementierte verdichtungsmittel, verfahren zu deren herstellung und verwendung
EP0691821A4 (de) Abnehmbare medizinische elektroden-anordnung
EP0612240A4 (de) Verfahren zur verlängerung der vaskulären verweildauer von partikelförmigen therapeutischen und diagnostischen wirkstoffen.
EP0731665A4 (de) Katheter-anordnung zur kartierenden erfassung und zur abtragung von vorhof-gewebe
DE69630946D1 (de) Modulares system zur patientenpflege
EP0836723A4 (de) Virtuelles medizinisches instrument zum midizinischen diagnostiktesten von patienten
EP0918534A4 (de) Medikamentenvorstufen auf peptidbasis und verfahren zur ihrer herstellung und nutzung
DE69520403D1 (de) Herzrhythmusmessgerät
EP0461245A4 (en) Radiolabeled proteins for diagnostic or therapeutic use
EP0757696A4 (de) Diagnose menschlichen spermas
FI965204A0 (fi) Bromelaiinin lääkekäyttö
FR2753376B1 (fr) Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
FR2747678B1 (fr) Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
FI973407L (fi) Kirurgin takki
EP0727959A4 (de) Diagnostische anwendungen von hydrazinoadenosine
FR2725023B1 (fr) Diagnostic direct d'haptenes
FI950389A0 (fi) Ny medicinsk anvaendning av hemiprodukter
FR2720944B1 (fr) Composition thérapeutique ou diététique sous forme de gel médicamenteux pour l'administration à des animaux de compagnie.
FI963263A0 (fi) Bromelaiinin lääkinnällinen käyttö
NO953003D0 (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 1/00 A, 7C 07K 14/00 B, 7C 07K 16/00 B, 7C 07K 17/00 B, 7C 12P 21/02 B, 7C 12P 21/04 B, 7C 12P 21/08 B, 7A 61K 39/395 B, 7A 61K 39/40 B, 7A 61K 39/42 B, 7A 61K 47/48 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010904

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE DK FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20020419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050417